My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Altimmune, Inc. - Common Stock (NQ:ALT)

4.810 +0.340 (+7.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday ↗

September 18, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About Altimmune ↗

August 13, 2025

Via Benzinga

Uncovering Potential: Altimmune's Earnings Preview ↗

August 11, 2025

Via Benzinga

Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns

August 19, 2025

San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet...

Via MarketMinute

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results ↗

August 13, 2025

Via Benzinga

Altimmune Q2 FY2025 Earnings Call Transcript ↗

August 12, 2025

Altimmune Q2 FY2025 earnings call transcript

Via Benzinga

Topics Earnings

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief ↗

June 28, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts ↗

June 27, 2025

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Via Benzinga

Top movers in Thursday's session ↗

June 26, 2025

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 26, 2025

Via Benzinga

Crude Oil Gains Over 1%; Walgreens Posts Upbeat Earnings ↗

June 26, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

June 26, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Gapping stocks in Thursday's session ↗

June 26, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

Altimmune Stock Sinks After Mid-Stage Data From Fatty Liver Candidate ↗

June 26, 2025

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.

Via Benzinga

Dow Surges 200 Points; US GDP Contracts 0.5% ↗

June 26, 2025

Via Benzinga

Topics Stocks

Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position ↗

June 26, 2025

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

Via Stocktwits

Thursday's pre-market session: top gainers and losers ↗

June 26, 2025

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

June 26, 2025

Via Benzinga

Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win ↗

June 25, 2025

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape.

Via Stocktwits

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. ↗

June 18, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? ↗

May 20, 2025

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.